<?xml version="1.0" encoding="UTF-8"?>
<response>

<lst name="responseHeader">
  <int name="status">0</int>
  <int name="QTime">25</int>
  <lst name="params">
    <str name="echoParams">explicit</str>
    <str name="indent">true</str>
    <str name="file">data-lines/./reut2-004.sgm-870.txt</str>
    <str name="usePOS">true</str>
    <str name="sentences">3</str>
    <str name="wt">xml</str>
    <str name="formula">augNorm_inverse</str>
  </lst>
</lst>
<lst name="analysis">
  <lst name="summary">
    <lst name="stats">
      <lst name="sentences">
        <int name="count">33</int>
      </lst>
      <lst name="terms">
        <int name="count">131</int>
      </lst>
      <lst name="stems">
        <int name="count">84</int>
      </lst>
    </lst>
    <lst name="terms">
      <lst name="term">
        <str name="text">liability</str>
        <double name="strength">1.0</double>
      </lst>
      <lst name="term">
        <str name="text">promise</str>
        <double name="strength">0.9999999999999979</double>
      </lst>
      <lst name="term">
        <str name="text">trials</str>
        <double name="strength">0.9934327593756572</double>
      </lst>
      <lst name="term">
        <str name="text">clinical</str>
        <double name="strength">0.9934327593756571</double>
      </lst>
      <lst name="term">
        <str name="text">effects</str>
        <double name="strength">0.9934327593756561</double>
      </lst>
    </lst>
    <lst name="sentences">
      <lst name="sentence">
        <str name="text">Jeffrey Levi, executive director of the National Gay and Lesbian Task Force, which is actively in AIDS policy and funding issues, cited the drug Suramin from Bayer AG &lt;BAYRY&gt;, which had shown early promise as an AIDS treatment, but on wider clinical testing was shown to have deadly side effects.</str>
        <int name="index">31</int>
        <int name="start">1</int>
        <int name="end">297</int>
        <double name="strength">1.0</double>
        <int name="terms">19</int>
      </lst>
      <lst name="sentence">
        <str name="text">The Reagan Administration's soon-to-be published proposals to make experimental therapies more rapidly and widely available to terminally ill patients pose product liability problems for drug companies, experts in the pharmaceutical field said.</str>
        <int name="index">0</int>
        <int name="start">0</int>
        <int name="end">244</int>
        <double name="strength">0.6973209710881826</double>
        <int name="terms">14</int>
      </lst>
      <lst name="sentence">
        <str name="text">"I find the proposal to be a very significant alteration of the FDA's past policies that should positively affect (drug companies') stocks," said drug analyst Davis Saks, with Morgan, Olmstead, Kennedy and Gardner.</str>
        <int name="index">25</int>
        <int name="start">1</int>
        <int name="end">215</int>
        <double name="strength">0.6970418949102758</double>
        <int name="terms">11</int>
      </lst>
    </lst>
    <lst name="highlighted">
      <lst name="sentence">
        <str name="text">&lt;em&gt;Jeffrey&lt;/em&gt; Levi, &lt;em&gt;executive director&lt;/em&gt; of the &lt;em&gt;National&lt;/em&gt; Gay and &lt;em&gt;Lesbian&lt;/em&gt; Task &lt;em&gt;Force,&lt;/em&gt; which is actively in AIDS &lt;em&gt;policy&lt;/em&gt; and &lt;em&gt;funding issues,&lt;/em&gt; cited the drug &lt;em&gt;Suramin&lt;/em&gt; from &lt;em&gt;Bayer&lt;/em&gt; AG &lt;&lt;em&gt;BAYRY&gt;,&lt;/em&gt; which had shown &lt;em&gt;early promise&lt;/em&gt; as an AIDS &lt;em&gt;treatment,&lt;/em&gt; but on wider &lt;em&gt;clinical testing&lt;/em&gt; was shown to have &lt;em&gt;deadly&lt;/em&gt; side &lt;em&gt;effects&lt;/em&gt;.</str>
        <int name="index">31</int>
      </lst>
      <lst name="sentence">
        <str name="text">The &lt;em&gt;Reagan Administration&lt;/em&gt;'s soon-to-be published &lt;em&gt;proposals&lt;/em&gt; to make &lt;em&gt;experimental therapies&lt;/em&gt; more rapidly and widely &lt;em&gt;available&lt;/em&gt; to terminally ill &lt;em&gt;patients&lt;/em&gt; pose &lt;em&gt;product liability problems&lt;/em&gt; for drug &lt;em&gt;companies, experts&lt;/em&gt; in the &lt;em&gt;pharmaceutical field said&lt;/em&gt;.</str>
        <int name="index">0</int>
      </lst>
      <lst name="sentence">
        <str name="text">"I find the &lt;em&gt;proposal&lt;/em&gt; to be a very &lt;em&gt;significant alteration&lt;/em&gt; of the FDA's past &lt;em&gt;policies&lt;/em&gt; that should positively &lt;em&gt;affect &lt;/em&gt;(drug &lt;em&gt;companies') stocks,"&lt;/em&gt; said drug &lt;em&gt;analyst&lt;/em&gt; Davis Saks, with &lt;em&gt;Morgan,&lt;/em&gt; Olmstead, &lt;em&gt;Kennedy&lt;/em&gt; and &lt;em&gt;Gardner&lt;/em&gt;.</str>
        <int name="index">25</int>
      </lst>
    </lst>
  </lst>
</lst>
</response>
